MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib J Bean, C Brennan, JY Shih, G Riely, A Viale, L Wang, D Chitale, N Motoi, ... Proceedings of the National Academy of Sciences 104 (52), 20932-20937, 2007 | 1872 | 2007 |
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study JC Soria, DSW Tan, R Chiari, YL Wu, L Paz-Ares, J Wolf, SL Geater, ... The Lancet 389 (10072), 917-929, 2017 | 1048 | 2017 |
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer YL Wu, M Tsuboi, J He, T John, C Grohe, M Majem, JW Goldman, ... New England Journal of Medicine 383 (18), 1711-1723, 2020 | 971 | 2020 |
MicroRNA signature predicts survival and relapse in lung cancer SL Yu, HY Chen, GC Chang, CY Chen, HW Chen, S Singh, CL Cheng, ... Cancer cell 13 (1), 48-57, 2008 | 957 | 2008 |
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3 … JCH Yang, LV Sequist, SL Geater, CM Tsai, TSK Mok, M Schuler, ... The lancet oncology 16 (7), 830-838, 2015 | 834 | 2015 |
Value of sonography in determining the nature of pleural effusion: analysis of 320 cases. PC Yang, KT Luh, DB Chang, HD Wu, CJ Yu, SH Kuo AJR. American journal of roentgenology 159 (1), 29-33, 1992 | 638 | 1992 |
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib … T Mok, YL Wu, JS Lee, CJ Yu, V Sriuranpong, J Sandoval-Tan, G Ladrera, ... Clinical Cancer Research 21 (14), 3196-3203, 2015 | 486 | 2015 |
Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung CancerUncommon EGFR … JY Wu, CJ Yu, YC Chang, CH Yang, JY Shih, PC Yang Clinical cancer research 17 (11), 3812-3821, 2011 | 455 | 2011 |
Mycobacterium abscessus complex infections in humans MR Lee, WH Sheng, CC Hung, CJ Yu, LN Lee, PR Hsueh Emerging infectious diseases 21 (9), 1638, 2015 | 443 | 2015 |
Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis JY Chien, JS Jerng, CJ Yu, PC Yang Critical care medicine 33 (8), 1688-1693, 2005 | 388 | 2005 |
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial YL Wu, JS Lee, S Thongprasert, CJ Yu, L Zhang, G Ladrera, ... The lancet oncology 14 (8), 777-786, 2013 | 385 | 2013 |
Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells YC Liu, HY Yen, CY Chen, CH Chen, PF Cheng, YH Juan, CH Chen, ... Proceedings of the National Academy of Sciences 108 (28), 11332-11337, 2011 | 362 | 2011 |
Pulmonary Sequelae in Convalescent Patients after Severe Acute Respiratory Syndrome: Evaluation with Thin-Section CT1 YC Chang, CJ Yu, SC Chang, JR Galvin, HM Liu, CH Hsiao, PH Kuo, ... Radiology 236 (3), 1067-1075, 2005 | 347 | 2005 |
Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response JY Wu, SG Wu, CH Yang, CH Gow, YL Chang, CJ Yu, JY Shih, PC Yang Clinical Cancer Research 14 (15), 4877-4882, 2008 | 334 | 2008 |
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia Q Lan, CA Hsiung, K Matsuo, YC Hong, A Seow, Z Wang, HD Hosgood III, ... Nature genetics 44 (12), 1330-1335, 2012 | 302 | 2012 |
Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line … CH Yang, CJ Yu, JY Shih, YC Chang, FC Hu, MC Tsai, KY Chen, ZZ Lin, ... Journal of Clinical Oncology 26 (16), 2745-2753, 2008 | 295 | 2008 |
Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma JY Shih, MF Tsai, TH Chang, YL Chang, A Yuan, CJ Yu, SB Lin, GY Liou, ... Clinical Cancer Research 11 (22), 8070-8078, 2005 | 284 | 2005 |
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. TS Mok, YL Wu, CJ Yu, C Zhou, YM Chen, L Zhang, J Ignacio, M Liao, ... Oncology, 2008 | 277 | 2008 |
Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome JY CHIEN, PR HSUEH, WC CHENG, CJ YU, PC YANG Respirology 11 (6), 715-722, 2006 | 271 | 2006 |
Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non–small-cell … A Yuan, CJ Yu, SH Kuo, WJ Chen, FY Lin, KT Luh, PC Yang, YC Lee Journal of clinical oncology 19 (2), 432-441, 2001 | 266 | 2001 |